Seek Returns

ICLR vs. ONC: ICON vs. BeOne Medicines Stock Comparison

How do ICON (ICLR) and BeOne Medicines (ONC) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

ICON (ICLR) and BeOne Medicines (ONC) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ICLR is classified in Life Sciences Tools & Services while ONC is classified in Biotechnology.

ICON (ICLR) trades as ordinary local shares, while BeOne Medicines (ONC) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Company profile comparison for ICON (ICLR) and BeOne Medicines (ONC)
Profile ItemICLRONC
NameICON plcBeOne Medicines Ltd. American Depositary Shares
Country/RegionIrelandSwitzerland
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & ServicesBiotechnology
GICS Sub-IndustryLife Sciences Tools & ServicesBiotechnology
Market Capitalization15.34 billion USD46.49 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateMay 15, 1998February 3, 2016
Security TypeCommon StockADR

Price Performance

Cumulative Growth

ICLR
ONC
GSPC
Loading price history…
ICON (ICLR) vs. BeOne Medicines (ONC), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for ICON (ICLR) and BeOne Medicines (ONC). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for ICON (ICLR) and BeOne Medicines (ONC). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for ICON (ICLR) and BeOne Medicines (ONC)
MetricICLRONC
Total Return (1Y)30.55%30.59%
Total Return (3Y, Annualized)-6.05%30.15%
Total Return (5Y, Annualized)-5.40%2.48%

Risk Profile

Drawdown History

ICLR
ONC
GSPC
Loading price history…
ICON (ICLR) vs. BeOne Medicines (ONC), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for ICON (ICLR) and BeOne Medicines (ONC). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for ICON (ICLR) and BeOne Medicines (ONC)
MetricICLRONC
Volatility (1Y, Annualized)68.62%35.90%
Beta (5Y)1.170.59
Max Drawdown (5Y)-76.87%-68.89%
Avg. Volume (3M)943.50K405.29K

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
ICLR and ONC are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for ICON (ICLR) and BeOne Medicines (ONC)
MetricICLRONC
Sharpe Ratio (1Y)0.380.73
Sortino Ratio (1Y)0.521.15

Profitability

ROE (TTM)

BeOne Medicines (ONC) at 18.40% sits in the top ROE quartile, while ICON (ICLR) at 4.70% is closer to the peer norm — stronger capital efficiency for ONC.

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.70%

Max
109.18%
Q3
6.23%
ICLR
4.70%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

ONC

Pharmaceuticals, Biotechnology & Life Sciences industry group

18.40%

Max
109.18%
ONC
18.40%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
ICON (ICLR) vs. BeOne Medicines (ONC): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

For every dollar of sales, both ICON (ICLR) at 5.26% and BeOne Medicines (ONC) at 13.86% retain more as net profit than most peers, landing in the top net margin quartile of their industries.

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.26%

Max
18.05%
ICLR
5.26%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

ONC

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.86%

Max
18.05%
ONC
13.86%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
ICON (ICLR) vs. BeOne Medicines (ONC): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

BeOne Medicines (ONC) at 22.15% operates in the top operating margin quartile, ahead of ICON (ICLR) at 10.73%, which runs around its industry’s norm.

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

10.73%

Max
83.12%
Q3
14.77%
ICLR
10.73%
Median
0.00%
Q1
-78.82%
Min
-207.40%

ONC

Pharmaceuticals, Biotechnology & Life Sciences industry group

22.15%

Max
83.12%
ONC
22.15%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
ICON (ICLR) vs. BeOne Medicines (ONC): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for ICON (ICLR) and BeOne Medicines (ONC)
MetricICLRONC
ROE (TTM)4.70%18.40%
ROA (TTM)0.85%8.42%
Net Margin (TTM)5.26%13.86%
Operating Margin (TTM)10.73%22.15%
Gross Margin (TTM)23.44%89.39%

Growth

Revenue Growth

Both ICON (ICLR) at 0.76% and BeOne Medicines (ONC) at 40.23% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Loading chart…
ICON (ICLR) vs. BeOne Medicines (ONC): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: ICON (ICLR) reports EPS growth of -71.56%, ranked against its industry; BeOne Medicines (ONC) has no EPS growth figure this period.

Loading chart…
ICON (ICLR) vs. BeOne Medicines (ONC): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for ICON (ICLR) and BeOne Medicines (ONC)
MetricICLRONC
Revenue Growth (YoY)0.76%40.23%
Revenue Growth (3Y CAGR)2.15%55.69%
EPS Growth (YoY)-71.56%--
EPS Growth (3Y CAGR)-23.82%--

Financial Strength

Current Ratio (MRQ)

BeOne Medicines (ONC) at 3.55 keeps current ratio within its industry’s typical mid-range, while ICON (ICLR) at 1.32 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for ICLR.

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.32

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
ICLR
1.32
Min
0.10

ONC

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.55

Max
25.13
Q3
12.13
Median
5.52
ONC
3.55
Q1
2.47
Min
0.10
Loading chart…
ICON (ICLR) vs. BeOne Medicines (ONC): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both ICON (ICLR) at 0.38 and BeOne Medicines (ONC) at 0.35 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.38

Max
1.42
Q3
0.65
ICLR
0.38
Median
0.15
Q1
0.02
Min
0.00

ONC

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.35

Max
1.42
Q3
0.65
ONC
0.35
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
ICON (ICLR) vs. BeOne Medicines (ONC): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for ICON (ICLR) and BeOne Medicines (ONC)
MetricICLRONC
Current Ratio (MRQ)1.323.55
Debt / Equity (MRQ)0.380.35
Net Debt / EBITDA5.55-2.80

Dividends

Dividend Yield (TTM)

Neither ICON (ICLR) nor BeOne Medicines (ONC) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ICLR
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

ONC

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ONC
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
ICON (ICLR) vs. BeOne Medicines (ONC): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither ICON (ICLR) nor BeOne Medicines (ONC) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ICLR
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

ONC

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ONC
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
ICON (ICLR) vs. BeOne Medicines (ONC): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for ICON (ICLR) and BeOne Medicines (ONC)
MetricICLRONC
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

P/E Ratio (TTM)

Both ICON (ICLR) at 81.90 and BeOne Medicines (ONC) at 52.17 sit in the richer earnings-multiple quartile for P/E ratio, so investors are paying more for TTM earnings than they pay for typical peers.

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

81.90

Max
85.34
ICLR
81.90
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07

ONC

Pharmaceuticals, Biotechnology & Life Sciences industry group

52.17

Max
85.34
ONC
52.17
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
Loading chart…
ICON (ICLR) vs. BeOne Medicines (ONC): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

ICON (ICLR) at 1.86 sits in the cheaper P/S ratio quartile while BeOne Medicines (ONC) at 7.04 prices around its industry’s middle — ICLR costs less per dollar of sales, though read it alongside growth and margins.

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.86

Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
ICLR
1.86
Min
0.01

ONC

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.04

Max
58.18
Q3
25.77
Median
7.30
ONC
7.04
Q1
3.01
Min
0.01
Loading chart…
ICON (ICLR) vs. BeOne Medicines (ONC): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

ICON (ICLR) at 1.68 looks cheap against book in the lower P/B ratio quartile, while BeOne Medicines (ONC) at 7.98 carries a premium in the upper quartile — a clear price-to-book gap.

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.68

Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
ICLR
1.68
Min
-5.59

ONC

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.98

Max
13.53
ONC
7.98
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
ICON (ICLR) vs. BeOne Medicines (ONC): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for ICON (ICLR) and BeOne Medicines (ONC)
MetricICLRONC
P/E Ratio (TTM)81.9052.17
P/S Ratio (TTM)1.867.04
P/B Ratio (MRQ)1.687.98
Free Cash Flow Yield (TTM)3.51%2.21%